Trivant Custom Portfolio Group LLC Invests $832,000 in Danaher Corporation (NYSE:DHR)

Trivant Custom Portfolio Group LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,060 shares of the conglomerate’s stock, valued at approximately $832,000.

Other institutional investors have also bought and sold shares of the company. FAS Wealth Partners Inc. lifted its holdings in shares of Danaher by 20.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock valued at $2,203,000 after acquiring an additional 1,639 shares during the period. ICICI Prudential Asset Management Co Ltd bought a new position in Danaher during the 4th quarter valued at about $4,591,000. Charles Schwab Investment Management Inc. lifted its holdings in Danaher by 3.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock valued at $933,524,000 after purchasing an additional 135,047 shares during the last quarter. Camden National Bank boosted its position in Danaher by 285.0% in the fourth quarter. Camden National Bank now owns 7,227 shares of the conglomerate’s stock valued at $1,659,000 after buying an additional 5,350 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock worth $1,303,163,000 after buying an additional 579,046 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Shares of DHR stock opened at $194.36 on Thursday. The firm’s 50 day moving average price is $193.46 and its two-hundred day moving average price is $210.32. The stock has a market cap of $139.10 billion, a PE ratio of 37.74, a PEG ratio of 2.75 and a beta of 0.77. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. As a group, analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. Danaher’s dividend payout ratio (DPR) is presently 24.85%.

Analyst Ratings Changes

DHR has been the topic of several recent analyst reports. Wells Fargo & Company reduced their target price on Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 23rd. Bank of America cut their price objective on Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Guggenheim restated a “buy” rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the company an “overweight” rating in a research note on Tuesday, April 22nd. Finally, Jefferies Financial Group decreased their price objective on shares of Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a report on Tuesday, April 22nd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.